REMINDER: Our user survey closes TODAY, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVolex Regulatory News (VLX)

Share Price Information for Volex (VLX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 344.00
Bid: 344.00
Ask: 346.00
Change: 2.00 (0.58%)
Spread: 2.00 (0.581%)
Open: 330.00
High: 345.00
Low: 330.00
Prev. Close: 342.00
VLX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Full Year Trading Update

18 Apr 2023 07:00

RNS Number : 4982W
Volex PLC
18 April 2023
 

 

Volex plc

 

("Volex", the "Group", or the "Company")

 

Full Year Trading Update

 

Strong organic growth with revenue and profit ahead of expectations

 

Volex (AIM: VLX), the specialist integrated manufacturer of critical power and data transmission products, today issues an update on trading for the 52 weeks ended 2 April 2023 (the "Year" or "FY2023").

 

Full year trading ahead of market expectations

 

Volex has continued its positive momentum and demonstrated further progress during the Year, reflecting its compelling positions in attractive markets with strong structural growth characteristics.

 

Revenue is now expected to be at least $710 million, representing an increase of at least 15.5% compared with the prior year. Underlying operating profit is now expected to be at least $66 million, at least 17.4% higher than the prior year, with both revenue and underlying operating profit ahead of market expectations1, 2.

 

An increase in gross margins and continued cost control improvements is expected to deliver a strengthening in underlying operating margins to 9.3% (FY2022: 9.1%). The Group has delivered margins within its targeted range for three years, managing inflationary cost challenges and demonstrating the strong competitive positioning.

 

Operating free cash flow in the second half of the Year was substantially higher than the first half. After capital investment, dividend payments and acquisition consideration of approximately $46 million in the Year, pre-IFRS 16 net debt is expected to be approximately $76 million. This is a reduction of $22 million since the half year and represents a covenant leverage of 1.0x3, comfortably below the Group's target leverage corridor.

 

Continued outperformance of underlying markets provides strong momentum into FY2024

 

Against a volatile backdrop in FY2023, Volex delivered strong organic growth, ahead of its underlying markets, which has been driven by continued execution of the Group's commercial strategy which focuses on:

 

· Targeting structural growth markets - with the Electric Vehicles, Complex Industrial Technology and Medical sectors all delivering strong constant currency organic revenue growth in FY2023. Pleasingly, the adverse impact of post-pandemic demand normalisation in the Consumer Electricals sector is being largely offset by market share gains

 

· Leveraging the Group's global footprint - which is enabling the Group to benefit from heightened levels of demand in a number of territories as a result of customers re-configuring supply chains to focus on partners with high service levels and local facilities

 

· Expanding the Group's range of capabilities - through targeted investment the Group has continued to expand its offering which has led to a high level of new project wins with both new and existing customers

 

Volex is well positioned to continue investing in sustainable organic growth with a robust balance sheet and healthy cash generation. The Group has an active acquisition pipeline of value enhancing opportunities, which will support the achievement of the five-year strategy to grow revenues to $1.2 billion by the end of FY2027.

 

Nat Rothschild, Executive Chairman, said: "I am delighted with the strong organic growth performance delivered by the business during the period. We continue to deliver against the long-term, strategic growth plan that we unveiled last year and I firmly believe that Volex's diverse global footprint, ongoing investment plans and reputation for excellence will continue to drive ongoing outperformance versus our competitors. This, combined with our robust balance sheet and healthy cash generation, means that the Group is well positioned as we enter the new financial year."

 

-ENDS-

 

 

For further information please contact:

Volex plc

Nat Rothschild, Executive Chairman

Jon Boaden, Chief Financial Officer

+44 (0)7747 488785

investor.relations@volex.com

 

Singer Capital Markets - Nominated Adviser & Joint Broker

Shaun Dobson

George Tzimas

+44 (0)20 7496 3000

 

HSBC Bank plc - Joint Broker

Simon Alexander

Joe Weaving

+44 (0)20 7991 8888

 

Powerscourt - Media Enquiries

James White

Nicholas Johnson 

 

+44 (0)20 7250 1446

 

Notes:

1. Underlying operating profit is before adjusting items which are one-off in nature and significant (such as restructuring costs, impairment charges or acquisition-related costs), the amortisation and impairment of acquired intangible assets and share-based payment charges. This trading update is based upon unaudited management accounts information. Forward-looking statements have been made by the Directors in good faith using information available up until the date that they approved this statement. Forward-looking statements should be regarded with caution because of the inherent uncertainties in economic trends and business risks.

 

2. The Company has compiled forecasts from five analysts with current market forecasts for the 52 weeks ending 2 April 2023 for revenue to be in the range of $690.5 million to $695.0 million, with a consensus of $692.9 million, and for underlying operating profit to be in the range of $62.3 million to $64.0 million, with a consensus of $62.9 million.

 

3. Covenant leverage represents the ratio of net debt, excluding operating lease liabilities, to EBITDA excluding the impact of right of use amortisation arising on operating lease arrangements. This measure is aligned with the covenant calculations used for external debt facilities.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFLDSDIDLIV
Date   Source Headline
19th Oct 20205:47 pmRNSHolding(s) in Company
15th Oct 20207:00 amRNSTrading Update
26th Aug 20205:02 pmRNSHolding(s) in Company
26th Aug 20208:57 amRNSDirector/PDMR Shareholding
19th Aug 20207:00 amRNSDirector/PDMR Shareholding
7th Aug 20205:06 pmRNSPDMR / PCA Dealing
5th Aug 202010:28 amRNSPDMR / PCA Dealing
30th Jul 20204:29 pmRNSCompany Secretary Change
30th Jul 20204:26 pmRNSResult of AGM
30th Jul 20207:00 amRNSAGM Statement
6th Jul 20203:41 pmRNSDirector/PDMR Shareholding
3rd Jul 20207:00 amRNSNotice of AGM and Annual Report and Accounts
26th Jun 20203:50 pmRNSHolding(s) in Company
26th Jun 20207:00 amRNSDirector/PDMR Shareholding and Total Voting Rights
23rd Jun 20207:00 amRNSDirector/PDMR Shareholding
22nd Jun 20206:23 pmRNSDirector/PDMR Shareholding
18th Jun 20207:01 amRNSInvestor Presentation
18th Jun 20207:00 amRNSPreliminary Group Results FY2020
1st Jun 20204:41 pmRNSSecond Price Monitoring Extn
1st Jun 20204:36 pmRNSPrice Monitoring Extension
29th Apr 20204:19 pmRNSDirector/PDMR Shareholding
24th Apr 20204:36 pmRNSPrice Monitoring Extension
20th Apr 20204:35 pmRNSPrice Monitoring Extension
16th Apr 20207:00 amRNSTrading Update
6th Apr 20204:35 pmRNSPrice Monitoring Extension
6th Apr 20201:31 pmRNSDirector/PDMR Shareholding
3rd Apr 20203:41 pmRNSDirector/PDMR Shareholding
1st Apr 20202:54 pmRNSDirector/PDMR Shareholding
30th Mar 20201:42 pmRNSDirector/PDMR Shareholding
25th Mar 20204:42 pmRNSSecond Price Monitoring Extn
25th Mar 20204:36 pmRNSPrice Monitoring Extension
24th Mar 20207:00 amRNSChange of Registered Office
23rd Mar 20204:41 pmRNSSecond Price Monitoring Extn
23rd Mar 20204:36 pmRNSPrice Monitoring Extension
19th Mar 20205:00 pmRNSDirector/PDMR Shareholding
19th Mar 202012:08 pmRNSSecond Price Monitoring Extn
19th Mar 202012:03 pmRNSPrice Monitoring Extension
11th Mar 20202:03 pmRNSHolding(s) in Company
9th Mar 20204:30 pmRNSDirector/PDMR Shareholding
6th Mar 20204:41 pmRNSSecond Price Monitoring Extn
6th Mar 20204:36 pmRNSPrice Monitoring Extension
6th Mar 202012:07 pmRNSSecond Price Monitoring Extn
6th Mar 202012:02 pmRNSPrice Monitoring Extension
2nd Mar 202012:47 pmRNSDeferred Consideration for Servatron Acquisition
26th Feb 20203:49 pmRNSEBT Share Purchase
17th Feb 20207:00 amRNSStatement Regarding Situation in China - Update
13th Feb 20205:26 pmRNSEBT Share Purchase
10th Feb 20209:57 amRNSStatement Regarding Current Situation in China
15th Jan 20203:47 pmRNSHolding(s) in Company
15th Jan 20203:34 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.